Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C: A cost-effectiveness analysis

Annals of Internal Medicine

Volumn 133, Issue 9, 2000, Pages 665-675

  Wong, J B ^a   Koff, R S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 0034619548     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-9-200011070-00008     Document Type: Article

References (70)

1. Statement: Management of hepatitis C
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
4. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group
5. Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time?
6. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm
7. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group
8. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
9. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
10. Pretreatment evaluation of chronic hepatitis C: Risks, benefits and costs
11. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome
12. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
13. Natural course of chronic hepatitis C
14. Progression of liver fibrosis in mild hepatitis C: A prospective study paired liver biopsy study
15. Natural history of chronic hepatitis C
16. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
17. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
18. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
19. Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients
20. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group
21. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors
22. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
23. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare
24. Liver transplantation for hepatitis C virus-related cirrhosis
25. Liver transplantation for chronic viral hepatitis
26. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up
27. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group
28. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen
29. Sampling variability on percutaneous liver biopsy
30. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver
31. Patient preferences for oral versus intravenous palliative chemotherapy
32. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach
33. Probabilistic sensitivity analysis incorporating the bootstrap: An example comparing treatments for the eradication of Helicobacter pylori
34. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group
35. Natural history of hepatitis C
36. Hepatitis C: The clinical spectrum of disease
37. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group
38. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
39. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
40. Hepatitis C: An economic evaluation of extended treatment with interferon
41. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
42. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group
43. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group
44. Health related quality of life in chronic hepatitis C is similar to that of other chronic disease states
45. Interferon and hepatocellular carcinoma
46. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis?
47. Can interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis?
48. Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?
49. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Societe Royale Belge de Gastro-enterologie
50. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics
51. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis
52. Virus elimination and histologic improvement in patients with chronic hepatitis C treated with interferon alpha
53. 10-Year follow-up after interferon-alfa therapy for chronic hepatitis C
54. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
55. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy
56. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
57. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis
58. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: A multivariate analysis in 343 patients
59. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group
60. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group
61. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis
62. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
63. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group
64. Therapy of hepatitis C: Patients with cirrhosis
65. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
66. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group